The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?
Eur J Radiol. 2021 Mar 11;138:109651. doi: 10.1016/j.ejrad.2021.109651. Online ahead of print.
Maxime Barat1, Thi Thuy Linh Nguyen2, Clémence Hollande3, Jean-Baptiste Coty4, Christine Hoeffel5, Benoit Terris6, Anthony Dohan4, Vincent Mallet3, Stanislas Pol3, Philippe Soyer4
Author information
1Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France; Université de Paris, 75006, Paris, France. Electronic address: maxime.barat@aphp.fr.
2Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France; Department of Radiology, Hue University of Medicine and Pharmacy, Hue University, Hue City, 530000, Viet Nam.
3Université de Paris, 75006, Paris, France; Department of Hepatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France.
4Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France; Université de Paris, 75006, Paris, France.
5Department of Radiology, Hôpital Robert Debré, CRESTIC, URCA, 51000, Reims, France.
6Université de Paris, 75006, Paris, France; Department of Pathology, Hôpital Cochin, AP-HP, 75014, Paris, France.
Abstract
Purpose: LI-RADS v2018 diagnostic system is used to diagnose hepatocellular carcinoma (HCC) in at risk patients. However, its applicability to HCC in non-alcoholic steatohepatitis (NASH) has not been specifically studied. The purpose of this study was to assess the applicability of LI-RADS v2018 diagnostic system for HCC in patients with NASH.
Materials and methods: The MRI examinations of 41 patients with HCC and NASH (NASH group) were reviewed and compared to those obtained in 41 patients with HCC and virus-induced chronic liver disease (Virus group). MRI examinations of the two groups were compared for imaging presentation, LI-RADS major criteria and LI-RADS categorization. Qualitative variables were compared using Fisher exact test and quantitative variables using Mann-Whitney U test Interreader agreement was assessed using kappa statistic.
Results: No significant differences in qualitative and quantitative variables were observed between the two groups. Most common findings in the two groups were hyperenhancement during the arterial phase and visibility on T2-weighted images (93 % vs. 98 %, P = 0.616 and 85 % vs. 88 %, P = 1.000 for NASH group and Virus group, respectively). No differences in prevalence between the two groups were found for any major LI-RADS v2018 criterion. Interreader agreement for LI-RADS categorization was strong for the NASH group (kappa = 0.802) and moderate for the virus group (kappa = 0.720). No differences were found between the two groups for LI-RADS categories (P = 0.303).
Conclusions: The LI-RADS v2018 diagnostic algorithm can be applied in patients with NASH.